Skip to main content

Elevation Oncology, Inc. (ELEV)

NASDAQ: ELEV · IEX Real-Time Price · USD
9.34 0.13 (1.41%)
Sep 20, 2021 9:38 AM EDT - Market open
Market Cap213.91M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out1.05M
EPS (ttm)-25.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume976
Open-
Previous Close9.21
Day's Range9.34 - 9.34
52-Week Range7.71 - 16.22
Betan/a
Analystsn/a
Price Target23.67 (+153.4%)
Est. Earnings DateNov 11, 2021

About ELEV

Elevation Oncology is a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. We utilize our deep expertise in developing drugs for rare, genomically-defined patient populations and strategic collaborations with our diagnostic collaborators to work towards a future where each tumor’s unique genomic test result can be matched with a purpose-built precision medicine. Our lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genom...

IndustryBiotechnology
IPO DateJun 25, 2021
CEOShawn Leland, Pharm.D., R.Ph.
Employees14
Stock ExchangeNASDAQ
Ticker SymbolELEV
Full Company Profile

Financial Performance

Financial Statements

News

Elevation Oncology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Sept. 7, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

1 week ago - PRNewsWire

Elevation Oncology Reports Second Quarter 2021 Financial Results

NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

1 month ago - PRNewsWire

Elevation Oncology to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 4, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically...

1 month ago - PRNewsWire

Elevation Oncology Announces Pricing of Initial Public Offering

NEW YORK, June 24, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

2 months ago - PRNewsWire

Elevation Oncology IPO Registration Document (S-1)

Elevation Oncology, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC